Shenzhen - Delayed Quote CNY
Luyan Pharma Co.,Ltd. (002788.SZ)
8.12
+0.04
+(0.50%)
At close: 3:04:15 PM GMT+8
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
20.51B
20.47B
19.85B
19.46B
17.55B
Cost of Revenue
19.00B
18.95B
18.34B
17.95B
16.17B
Gross Profit
1.51B
1.52B
1.51B
1.52B
1.37B
Operating Expense
836.52M
833.54M
788.42M
769.94M
732.94M
Operating Income
671.89M
690.98M
720.64M
745.22M
638.24M
Net Non Operating Interest Income Expense
-206.99M
-210.68M
-222.88M
-220.16M
-191.34M
Pretax Income
440.28M
453.27M
469.42M
466.01M
415.22M
Tax Provision
106.35M
105.58M
104.93M
115.04M
110.60M
Net Income Common Stockholders
333.19M
345.64M
363.53M
345.16M
305.87M
Basic EPS
0.85
0.89
0.94
0.89
0.79
Diluted EPS
0.85
0.89
0.94
0.89
0.79
Basic Average Shares
392.22M
388.36M
386.73M
387.82M
387.18M
Diluted Average Shares
--
--
--
--
387.18M
Total Operating Income as Reported
445.18M
458.10M
468.56M
465.94M
405.88M
Rent Expense Supplemental
--
2.57M
1.40M
2.36M
61.54M
Total Expenses
19.84B
19.78B
19.12B
18.72B
16.91B
Net Income from Continuing & Discontinued Operation
333.19M
345.64M
363.53M
345.16M
305.87M
Normalized Income
337.70M
353.65M
384.16M
386.82M
339.48M
Interest Income
2.98M
3.84M
5.14M
3.86M
-1.04M
Interest Expense
203.89M
206.68M
222.85M
219.10M
184.06M
Net Interest Income
-206.99M
-210.68M
-222.88M
-220.16M
-191.34M
EBIT
644.17M
659.96M
692.27M
685.11M
599.28M
EBITDA
644.17M
793.83M
819.73M
807.93M
712.05M
Reconciled Cost of Revenue
19.00B
18.95B
18.34B
17.95B
16.17B
Reconciled Depreciation
--
131.12M
120.61M
112.78M
112.77M
Net Income from Continuing Operation Net Minority Interest
333.19M
345.64M
363.53M
345.16M
305.87M
Total Unusual Items Excluding Goodwill
-5.95M
-10.43M
-26.57M
-55.32M
-45.81M
Total Unusual Items
-5.95M
-10.43M
-26.57M
-55.32M
-45.81M
Normalized EBITDA
650.12M
804.26M
846.30M
863.25M
757.86M
Tax Rate for Calcs
0.24
0.23
0.22
0.25
0.27
Tax Effect of Unusual Items
-1.44M
-2.43M
-5.94M
-13.66M
-12.20M
12/31/2021 - 2/18/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade